Is Tiziana Life Sciences Ltd (TLSA) a Buy, Sell, or Hold?
NASDAQ : TLSA
Tiziana Life Sciences Ltd
$0.8925 USD
-$0.13 (-12.5%)
- Volume
- 323.8K
- Average Volume
- 230.87K
- Market Capitalization
- $56.79M
- P/E Ratio
- -4.10
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $2.60
- Year Low
- $0.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.79
Company Overview
NASDAQ
Ivor R. Elrifi
Biotechnology
Healthcare
TLSA
10
BM
USD
Liquidity Metrics
0.01
8.79
8.79
8.25
0.00
Sales & Valuation
-$
0.00
2.33
0.00
-0.17
Profitability
-$0.32
-$18.43M
0.00%
0.00%
-125.84%
-36.98%
P/E Metrics
-4.10
-0.04
-0.04
Analyst Price Target & Rating
1/5
3 Analysts
%
Financial Health Scores
-15.38
1/9
-$2.66M
$11.5M
$11.44M
-$42.68M
Key Metrics (TTM)
-$65.27M
0.00
2.33
8.79
-125.84%
-41.20%
-24.57%
%
0 days
Company Executives
| Name | Title |
|---|---|
| Ivor R. Elrifi | Chief Executive Officer & Executive Director |
| William Edward Tente | Chief Regulatory Officer |
| Keeren Shah | Chief Operating Officer & Chief Financial Officer |
| Gabriele Marco Antonio Cerrone | Founder & Executive Chairman |
| Napoleone Ferrara | Member of Scientific Advisory Board |
| Richard K. Kim | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Tiziana Life Sciences Ltd (NASDAQ:TLSA) Stock
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) ... mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
2026-07-22 07:00:00
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.
Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities
2026-06-25 11:31:00
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its investor day, prompting analysts at Bank of America and...
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
2026-06-25 09:06:39
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS), with topline data expected in late Q3 or early Q4 2026. The company said results are planned to be presented at the 10th joint ACTRIMS-ECTRIMS meeting in Toronto in October 2026.
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
2026-06-25 07:00:00
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Progressive Multiple Sclerosis BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the last patient in its ongoing Phase 2a clinical trial has received their first dose of intranasal foralumab for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
2026-06-15 07:00:00
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr.
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
2026-05-28 07:00:00
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City.
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference
2026-05-28 06:07:00
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and...
FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says
2026-05-25 06:32:00
UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as the company gets ready to spin off its freight business...
Frequently Asked Questions
-
What is the current Tiziana Life Sciences Ltd (TLSA) stock price?
-
Tiziana Life Sciences Ltd(NASDAQ:TLSA) stock price is $0.8925 in the last trading session. During the trading session, TLSA stock reached the peak price of $2.6 while $0.8663 was the lowest point it dropped to. The percentage change in TLSA stock occurred in the recent session was --12.5% while the dollar amount for the price change in TLSA stock was -$0.13.
-
TLSA's industry and sector of operation?
-
The NASDAQ listed TLSA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TLSA?
-
Ivor R. Elrifi | Chief Executive Officer & Executive Director
William Edward Tente | Chief Regulatory Officer
Keeren Shah | Chief Operating Officer & Chief Financial Officer
Gabriele Marco Antonio Cerrone | Founder & Executive Chairman
Napoleone Ferrara | Member of Scientific Advisory Board -
How many employees does TLSA have?
-
Number of TLSA employees currently stands at 10. TLSA operates from 55 Park Lane, London, None W1K 1NA, BM.
-
Link for TLSA official website?
-
Official Website of TLSA is: https://www.tizianalifesciences.com
-
How do I contact TLSA?
-
TLSA could be contacted at phone #44 20 7495 2379 and can also be accessed through its website. TLSA operates from 55 Park Lane, London, None W1K 1NA, BM.
-
How many shares of TLSA are traded daily?
-
The average number of TLSA shares traded daily for last 3 months was 230.87K.
-
What is the market cap of TLSA currently?
-
The market value of TLSA currently stands at $56.79M with its latest stock price at $0.8925